Patrick Forde, Professor at The Johns Hopkins University, shared on X:
“The (to my mind) excessive scepticism of biotech analysts/journalists and many thoracic oncologists to ivo/PD1-VEGF bispecifics seems to be turning to sensible equipoise over WCLC 2026 next stop (irrational?) exuberance!”
You can also read:
IASLC Full Membership Is Open to the Global Thoracic Oncology Community
